Imaging: Prostate Cancer VL

The Use of Novel Imaging Methods in Prostate Cancer - Stefano Fanti

Details
Stefano Fanti joins Phillip Koo at the 2019 European Associate of Urology to discuss the use of novel imaging methods in the prostate cancer space. Their discussion highlights the excitement and limitations around imaging including the methods of MRI and PET, and its impacts on patient care. Biographies: Stefano Fanti, Professor Department of Experimental, Diagnostic and Specialty Medicine - DIMES...

Insights on Nuclear Imaging for Prostate Cancer- Stefano Fanti

Details
Stefano Fanti reviews the consensus paper on nuclear imaging for prostate cancer which was recently published in Lancet Oncology in December 2018. PSMA PET should be offered early in biochemical recurrence as it is the most sensitive and the EAU has incorporated PSMA PET into their guidelines as well, recommending PSMA PET for PSA >0.2. Stefano and Alicia discuss the various PSMA technologies and...

Incorporate Next Generation Imaging Tools Into Clinical Practice - Piet Ost

Details
Piet Ost shares details of his recent presentation focusing on biochemical recurrent prostate cancer, specifically in the recurrent setting, and answering the question such as should we be investing in this novel imaging for all patients or should we dial back a bit and only have that for selected patients? Who should get this imaging? He expressed his intent to try to convince people to think bef...

Definitions and Concepts of Oligometastatic Prostate Cancer- Interview with Robert Reiter

Details
Robert Reiter and Phillip Koo discuss his lecture on oligometastatic disease at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Reiter highlights next-generation imaging and its impact on managing patients with oligometastatic disease. Biographies: Robert E. Reiter, MD, MBA, the Bing Professor of Urologic Oncology and Director of UCLA's prostate cancer program, Director of Urol...

The Future of Advanced Prostate Cancer Imaging Presentation - Stefano Fanti

Details
Stefano Fanti presents his point of view on the future of prostate cancer imaging at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He shares his thoughts on the use of conventional imaging such as CT and bone scan and why they should be regarded as obsolete, and why novel imaging such as PET PSMA and MRI should be incorporated into practice immediately. Dr. Fanti believes that th...

18F-fluciclovine PET/CT in Patients with Suspected Recurrent Prostate Cancer - Bital Savir-Baruch

Details
Phillip Koo welcomes Bital Savir-Baruch who is presenting a review of prostate cancer imaging with 18F-FACBC fluciclovine (Axumin®) in men with suspected prostate cancer recurrence. Dr. Baruch reviews the benefits of this technology including earlier detection of recurrent disease as compared to conventional imaging, inability of the tracer to be metabolized and the slow urinary excretion. While d...

Disruptive Technologies in Radiology & Nuclear Medicine - Phillip Koo

Details
Phillip Koo and Alicia Morgans discuss disruptive changes impacting clinical practice. Clearly, medical practice disruptions occur more incrementally than when we think of what this means in consumer-based areas and yet each day new data from key clinical trials has the potential to shake up what is viewed-as the current standard of care. New data is challenging radiology and nuclear medicine as w...

Advancements in PSMA PET/CT Imaging - Phil Koo and Jeremie Calais

Details
Nuclear Medicine physician at UCLA, Jeremie Calais joins Phillip Koo in discussion on PSMA based PET imaging, the state of the field at his facility, UCLA, advancements in previous years, and they take a deeper dive into the diagnostic and therapeutic setting of PSMA imaging and the outlook in the new year. Biographies: Jeremie Calais, MD, MSc Assistant Professor at the Ahmanson Translational Imag...

The Optimal Treatment for Gleason Score 9-10 Prostate Cancer - Daniel Spratt

Details
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Biographies: Daniel Spratt, MD, Assistant Professor, Vice Chair, Clinical Research Chair, Division of Genitourinary Clinical Research Chief, Genitourinary Radiotherapy Program Department of Radiation Oncology, University of Michigan. Alicia Morgans, MD, MPH Ref...

SpaceOAR® Hydrogel Procedure Demonstration- Juan Montoya

Details
(Length of Presentation: 10 min) Juan Montoya, Urologist, and President of the Urology Center of Colorado demonstrates the application technique for SpaceOAR® Hydrogel. A temporary space which separates the prostate from the rectum. With this separation, the volume of normal tissue exposed to the radiation is greatly reduced, potentially dramatically lowering the complications related to radiother...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe